Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Biosensors
      • Chromatography
      • Flow Cytometry
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
LC–MS strategies for advanced modalities: ADC, AOC, multidomain and RNA therapeutics 3 days 15 hours 24 mins 54 secs REGISTER NOW

Spotlight survey on antibody-drug conjugates

14 Apr 2015
General interest

As part of our Spotlight on antibody-drug conjugates (ADCs), Bioanalysis Zone carried out a survey to investigate the techniques used to study ADCs, the issues surrounding their analysis, as well as what the future may hold.

The results can be seen via our infographic. We will also be analyzing the results of the survey during our Spotlight panel discussion, which you can register for here.

 

Top content

  • eBook: Precision bioanalysis for every molecule
  • Global initiative seeks to fast-track personalized therapies for rare diseases
  • Editor’s highlights from NextGen Biomed 2026

Related tags

ADCs
Previous article Next article

Related articles

8 OCT 2014 MS (LC–MS/MS, HRMS, IMS)
Developing successful bioanalytical strategies for antibody–drug conjugates
30 JUL 2015 LBA
Considerations when developing ligand binding assays to support ADC programs
13 JUL 2016 JOURNAL ARTICLES
Antibody–drug conjugate bioanalysis using LB-LC–MS/MS hybrid assays: strategies, methodology and correlation to ligand-binding assays
13 APR 2015 DRUG DEVELOPMENT
Bioanalysis of antibody–drug conjugates: American Association of Pharmaceutical Scientists antibody–drug conjugate working group position paper
22 JUN 2015 GENERAL INTEREST
Interview with Brian Rago (Pfizer) on ADC bioanalysis and how the community can overcome the associated challenges
19 AUG 2015 CHROMATOGRAPHY
Commentary on bioanalysis of ADCs survey results
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility
  • Editorial Policies

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Bioanalysis Zone